These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3616289)

  • 1. Effects on overviews of early stopping rules for clinical trials.
    Green SJ; Fleming TR; Emerson S
    Stat Med; 1987; 6(3):361-9. PubMed ID: 3616289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of overviews of randomized trials.
    Hennekens CH; Buring JE; Hebert PR
    Stat Med; 1987; 6(3):397-409. PubMed ID: 3616292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretation of results from subset analyses within overviews of randomized clinical trials.
    Gelber RD; Goldhirsch A
    Stat Med; 1987; 6(3):371-88. PubMed ID: 3616290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of stopping rules on heterogeneity of results in overviews of clinical trials.
    Hughes MD; Freedman LS; Pocock SJ
    Biometrics; 1992 Mar; 48(1):41-53. PubMed ID: 1581492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of overviews in cancer therapeutics.
    Simon R
    Stat Med; 1987; 6(3):389-96. PubMed ID: 3616291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research.
    Wang H; Rosner GL; Goodman SN
    Clin Trials; 2016 Dec; 13(6):621-631. PubMed ID: 27271682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obtaining medically meaningful answers from an overview of randomized clinical trials.
    Yusuf S
    Stat Med; 1987; 6(3):281-94. PubMed ID: 3616284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Workshop on Early Stopping Rules in Cancer Clinical Trials. Cambridge, United Kingdom, 13-15 April 1993.
    Stat Med; 1994 Jul 15-30; 13(13-14):1289-499. PubMed ID: 7973209
    [No Abstract]   [Full Text] [Related]  

  • 9. Size of cancer clinical trials and stopping rules.
    Pocock SJ
    Br J Cancer; 1978 Dec; 38(6):757-66. PubMed ID: 369589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-tailed tests and a statistical significance at 0.05: what do they mean?
    Campbell M
    Midwifery; 2004 Jun; 20(2):142-3. PubMed ID: 15177857
    [No Abstract]   [Full Text] [Related]  

  • 11. Stopping rules for phase II studies.
    Stallard N; Whitehead J; Todd S; Whitehead A
    Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?
    Prasad V; Vandross A
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):521-4. PubMed ID: 24474554
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of bias in overviews of reviews: a scoping review of methodological guidance and four-item checklist.
    Ballard M; Montgomery P
    Res Synth Methods; 2017 Mar; 8(1):92-108. PubMed ID: 28074553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim analyses and stopping rules in cancer clinical trials.
    Whitehead J
    Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policies for study monitoring and interim reporting of results.
    Green SJ; Fleming TR; O'Fallon JR
    J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designs for efficient clinical trials.
    Simon R
    Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rules on reporting trials must be better enforced, say health integrity groups.
    Cohen D
    BMJ; 2017 Dec; 359():j5786. PubMed ID: 29237599
    [No Abstract]   [Full Text] [Related]  

  • 18. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data.
    Hemmings R; Day S
    Drug Saf; 2004; 27(1):1-6. PubMed ID: 14720083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of clinical trials in patients with urinary tract infections.
    Norrby SR
    Infection; 1992; 20 Suppl 3():S181-8; discussion S189-92. PubMed ID: 1490745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.